Abatacept as a Long-Term Targeted Therapy for LRBA Deficiency
- 1 November 2019
- journal article
- research article
- Published by Elsevier in The Journal of Allergy and Clinical Immunology: In Practice
- Vol. 7 (8) , 2790-2800.e15
Abstract
No abstract availableKeywords
Funding Information
- National Institutes of Health
- Türkiye Bilimsel ve Teknolojik Araştırma Kurumu
This publication has 18 references indexed in Scilit:
- Two male siblings with a novel LRBA mutation presenting with different findings of IPEX syndromeJMM Case Reports, 2018
- Exaggerated follicular helper T-cell responses in patients with LRBA deficiency caused by failure of CTLA4-mediated regulationJournal of Allergy and Clinical Immunology, 2018
- Treatment of severe forms of LPS-responsive beige-like anchor protein deficiency with allogeneic hematopoietic stem cell transplantationJournal of Allergy and Clinical Immunology, 2018
- Multiple Presentations of LRBA Deficiency: a Single-Center ExperienceJournal of Clinical Immunology, 2017
- EFIS Lecture: Understanding the CTLA-4 checkpoint in the maintenance of immune homeostasisImmunology Letters, 2017
- CHAI and LATAIE: new genetic diseases of CTLA-4 checkpoint insufficiencyBlood, 2016
- The extended phenotype of LPS-responsive beige-like anchor protein (LRBA) deficiencyJournal of Allergy and Clinical Immunology, 2016
- Regulatory T-cell deficiency and immune dysregulation, polyendocrinopathy, enteropathy, X-linked–like disorder caused by loss-of-function mutations in LRBAJournal of Allergy and Clinical Immunology, 2015
- Autosomal dominant immune dysregulation syndrome in humans with CTLA4 mutationsNature Medicine, 2014
- Clinical Heterogeneity of Immunodysregulation, Polyendocrinopathy, Enteropathy, X-linked: Pulmonary Involvement as a Non-Classical Disease ManifestationJournal of Clinical Immunology, 2014